Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
N Engl J Med. 2012 Feb 16;366(7):619-28. doi: 10.1056/NEJMoa1110186.
Dilated cardiomyopathy and hypertrophic cardiomyopathy arise from mutations in many genes. TTN, the gene encoding the sarcomere protein titin, has been insufficiently analyzed for cardiomyopathy mutations because of its enormous size.
We analyzed TTN in 312 subjects with dilated cardiomyopathy, 231 subjects with hypertrophic cardiomyopathy, and 249 controls by using next-generation or dideoxy sequencing. We evaluated deleterious variants for cosegregation in families and assessed clinical characteristics.
We identified 72 unique mutations (25 nonsense, 23 frameshift, 23 splicing, and 1 large tandem insertion) that altered full-length titin. Among subjects studied by means of next-generation sequencing, the frequency of TTN mutations was significantly higher among subjects with dilated cardiomyopathy (54 of 203 [27%]) than among subjects with hypertrophic cardiomyopathy (3 of 231 [1%], P=3×10(-16)) or controls (7 of 249 [3%], P=9×10(-14)). TTN mutations cosegregated with dilated cardiomyopathy in families (combined lod score, 11.1) with high (>95%) observed penetrance after the age of 40 years. Mutations associated with dilated cardiomyopathy were overrepresented in the titin A-band but were absent from the Z-disk and M-band regions of titin (P≤0.01 for all comparisons). Overall, the rates of cardiac outcomes were similar in subjects with and those without TTN mutations, but adverse events occurred earlier in male mutation carriers than in female carriers (P=4×10(-5)).
TTN truncating mutations are a common cause of dilated cardiomyopathy, occurring in approximately 25% of familial cases of idiopathic dilated cardiomyopathy and in 18% of sporadic cases. Incorporation of sequencing approaches that detect TTN truncations into genetic testing for dilated cardiomyopathy should substantially increase test sensitivity, thereby allowing earlier diagnosis and therapeutic intervention for many patients with dilated cardiomyopathy. Defining the functional effects of TTN truncating mutations should improve our understanding of the pathophysiology of dilated cardiomyopathy. (Funded by the Howard Hughes Medical Institute and others.).
扩张型心肌病和肥厚型心肌病是由许多基因的突变引起的。编码肌节蛋白titin 的基因 TTN 由于其巨大的大小,对于心肌病突变的分析还不够充分。
我们通过下一代或双脱氧测序分析了 312 名扩张型心肌病患者、231 名肥厚型心肌病患者和 249 名对照者的 TTN。我们评估了家系中有害变异的共分离,并评估了临床特征。
我们发现了 72 个独特的突变(25 个无义突变,23 个移码突变,23 个剪接突变和 1 个大片段串联插入),这些突变改变了全长 titin。在通过下一代测序研究的受试者中,扩张型心肌病患者 TTN 突变的频率明显高于肥厚型心肌病患者(203 例中的 54 例[27%])(3 例肥厚型心肌病患者中的 231 例[1%],P=3×10(-16))或对照者(249 例中的 7 例[3%],P=9×10(-14))。TTN 突变在家系中与扩张型心肌病共分离(综合对数优势评分,11.1),在 40 岁后具有高(>95%)的观察到的外显率。与扩张型心肌病相关的突变在 titin A 带中过度表达,但不存在于 titin 的 Z 盘和 M 带区域(所有比较的 P 值均≤0.01)。总的来说,有 TTN 突变和无 TTN 突变的患者的心脏结局发生率相似,但男性突变携带者的不良事件发生早于女性携带者(P=4×10(-5))。
TTN 截断突变是扩张型心肌病的一个常见原因,在约 25%的特发性扩张型心肌病家族病例和 18%的散发性病例中发生。将检测 TTN 截断的测序方法纳入扩张型心肌病的基因检测中,应显著提高检测的灵敏度,从而使许多扩张型心肌病患者能够更早地诊断和治疗。确定 TTN 截断突变的功能影响应能提高我们对扩张型心肌病病理生理学的理解。(由霍华德·休斯医学研究所等资助)。